Clock.bio Secures $5.3 Million in Seed Funding
In recent news, clock.bio has successfully raised $5.3 million in seed funding, with LocalGlobe leading the round. Other participants included BlueYard Capital, Onsight Ventures, and Dr. Jonathan Milner, founder of Abcam. This funding marks a significant advancement in clock.bio's journey to decode the complex biological factors involved in human rejuvenation.
Understanding the Science of Rejuvenation
Clock.bio focuses on the intriguing potential of stem cells, which have the remarkable capability to reverse aging effects. The company works with human induced pluripotent stem cells (iPSCs) to create a proprietary aging model, successfully simulating the aging process while also facilitating a mechanism for rejuvenation. iPSCs exhibit the ability to repair themselves, restoring their youthful functionality.
Decoding the Atlas of Rejuvenation Factors
The research team at clock.bio has taken bold steps, utilizing a genome-wide CRISPR screen combined with single-cell RNA-sequencing techniques. This comprehensive approach analyzed over 3 million cells and generated a staggering 20 terabytes of data. As a result, they identified more than 100 genes that form an "Atlas of Rejuvenation Factors," integral to understanding the mechanisms of rejuvenation.
Future Directions for clock.bio
With this newfound knowledge, the focus now turns to validating these gene targets in somatic cells, elaborating the pathways involved, and linking them to specific aging-related diseases. Clock.bio believes that knowing these genetic markers related to rejuvenation will allow them to reverse aging signs through the repurposing of existing medications, enhancing overall healthspan.
Motivation Behind the Research
Markus Gstöttner, the CEO of clock.bio, expressed, "Our vision is to extend human healthspan to align with the global increase in longevity. Our methodology decodes significant components of human biology, bolstering our confidence in the translatability of our findings." The ongoing CRISPR screens provide numerous targets for exploration, leading to innovative discoveries in rejuvenation biology.
Support for Innovative Research
Investors are enthusiastic about the potential of clock.bio’s revolutionary approach to rejuvenation. Ferdi Sigona from LocalGlobe emphasized the uniqueness and speed of the company's method in investigating aging biology. With the support of investors, clock.bio aims to transform their discoveries into clinical applications that could potentially redefine the treatment of age-related diseases.
Building for the Future
The funding achieved will empower clock.bio in its mission to validate its atlas and prioritize target genes. Additionally, the company has augmented its team with vital hires, welcoming both Markus Gstöttner and Rodrigo Santos into leadership roles. Together with Mark Kotter, chairman, and co-founder, the clock.bio team is fully committed to advancing their research while seeking the right partnerships to launch clinical trials.
About clock.bio
Clock.bio is a forward-thinking biotech company dedicated to enhancing the human healthspan via innovative treatments that address age-related diseases. Their approach hinges on understanding rejuvenation programs inherent in human cells. Clock.bio promotes a partnership model that unites scientists and operators committed to making rejuvenation treatments universally accessible. For further insights into their groundbreaking work, visit www.clock.bio.
Frequently Asked Questions
What is clock.bio focused on?
Clock.bio aims to understand and utilize the biological mechanisms of rejuvenation to enhance human healthspan and combat age-related diseases.
How much funding did clock.bio raise?
Clock.bio recently secured $5.3 million in seed funding, primarily led by LocalGlobe.
What is an Atlas of Rejuvenation Factors?
This atlas comprises over 100 genes identified by clock.bio that are crucial to the rejuvenation process within human stem cells.
Who are the key investors in clock.bio?
The funding round saw participation from LocalGlobe, BlueYard Capital, Onsight Ventures, and Dr. Jonathan Milner.
How will clock.bio utilize the funding?
The funding will aid in the validation of gene targets and the development of their findings into potential clinical applications.
